organization · Reporting owner
FS Development Holdings, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.GMTX · Entity 2273 | 10% owner · Director by Deputization | February 05, 2021 | February 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date February 05, 2021 · Filed February 09, 2021
Jointly reported with Foresite Capital Fund V, L.P., Foresite Capital Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,500,000 |
Reported balance
After 2021-02-05 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-02-05 · Grant · Acquired 1,500,000 · Balance 1,500,000 F1: Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021. F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 2,928,750 |
Reported balance
After 2021-02-05 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-02-05 · Conversion · Acquired 2,928,750 · Balance 2,928,750 F3: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 441,500 |
Reported balance
Holding disclosure · report date 2021-02-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 441,500 F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-02-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-02-05 · Conversion · Disposed 2,928,750 · Balance 0 F3: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021.
F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.
F3: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer .
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2021 Filed Feb 9, 2021 20:04 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | ConversionCommon Stock · Derivative | 2,928,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-007713 · ownership.xml · derivative · entry 4 FS Development Holdings, LLC · CIK 0001820810 · 10% owner · Director by Deputization Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner · Director by Deputization Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner · Director by Deputization Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner · Director by Deputization Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,928,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F3 · derivative.exercise_date: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F3 · derivative.expiration_date: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F2 · ownership.direct: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 20:04 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | ConversionCommon Stock | 2,928,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-007713 · ownership.xml · nonDerivative · entry 2 FS Development Holdings, LLC · CIK 0001820810 · 10% owner · Director by Deputization Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner · Director by Deputization Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner · Director by Deputization Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner · Director by Deputization Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,928,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F2 · ownership.direct: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 20:04 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantCommon Stock | 1,500,000 | $10.00 | $15,000,000.00 |
DisclosureSEC source: 0001213900-21-007713 · ownership.xml · nonDerivative · entry 1 FS Development Holdings, LLC · CIK 0001820810 · 10% owner · Director by Deputization Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner · Director by Deputization Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner · Director by Deputization Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner · Director by Deputization Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 F1 · kind: Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021. F2 · ownership.direct: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| August 14, 2020 Filed Oct 20, 2020 00:49 UTC | Disc Medicine, Inc. FSDC · Entity 2273 | PurchaseClass A Common Stock | 441,500 | $10.00 | $4,415,000.00 |
DisclosureSEC source: 0001213900-20-032139 · ownership.xml · nonDerivative · entry 1 FS Development Holdings, LLC · CIK 0001820810 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Tananbaum James B. · CIK 0001581754 · Director · President & CEO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,500 F1 · date: The transaction was inadvertently omitted from reporting due to an administrative oversight. F2 · kind: The reported shares of Class A common stock were purchased in a private placement by FS Development Holdings, LLC (the "Sponsor") for $10.00 per share, as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-240098). F3 · ownership.direct: The Sponsor is the record holder of the shares reported herein. Foresite Capital Fund V, L.P. ("Fund V"), its general partner Foresite Capital Management V, LLC ("FCM V"), and Dr. James Tananbaum, the managing member of FCM V, have voting and investment discretion with respect to the common stock held of record by the Sponsor. Each of Fund V, FCM V, their respective members and Dr. Tananbaum disclaim beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.